The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.
In the broader context, Eli Lilly’s Retatrutide shows stronger peak weight loss efficacy, with results nearing 25–30%, surpassing both CagriSema and Zepbound ... of the curve, that even ...
While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...
The National on MSN10d
Two years on, are GLP-1 drugs such as Ozempic and Mounjaro here to stay?The click-baity headlines surrounding Ozempic, including “the skinny jab” and “Hollywood's best-kept secret”, came thick and ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Manufactured by Eli Lilly and Company, Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable prescription medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback